Navigation Links
Cepheid Reports 2013 First Quarter Results

SUNNYVALE, Calif., April 18, 2013 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today reported revenues for the first quarter of 2013 of $91.9 million, representing growth of 19% from $77.3 million for the first quarter of 2012.  Net income was $0.3 million, or $0.00 per share, which compares to net loss of $5.5 million, or $(0.08) per share, in the first quarter of 2012. 

Excluding employee stock-based compensation and amortization of purchased intangible assets, non-GAAP net income for the first quarter of 2013 was $7.8 million, or $0.11 per share.  This compares to a non-GAAP net loss of $1.2 million, or $(0.02) per share, in the first quarter of 2012.

"This was a solid start to 2013 for Cepheid with strong performance in our commercial clinical reagents driven both by broader test menu utilization by our installed base of more than 3,000 commercial GeneXpert® system customers globally and by new customer adoption," said John Bishop, Cepheid's Chairman and Chief Executive Officer.  "Our leading portfolio of molecular HAI tests continues to drive Cepheid's growth, but we were particularly pleased with the very strong level of interest in Xpert CT/NG in the first quarter, with about 10% of our North American installed base already using or validating the assay." 

Operational Overview

  • By business, total sales were, in millions:
  • Three Months Ended March 31,20132012ChangeClinical Systems

    2.50%Clinical Reagents

    67.154.423%Total Clinical 79.666.919%Non-Clinical & Other

    12.310.418%Total Sales$

  • By geography, total sales were, in millions:
  • Three Months Ended March 31,20132012ChangeNorth AmericaClinical

    45.515%Non-Clinical & Other

    11.48.928%Total North America63.654.417%InternationalClinical

    27.421.428%Non-Clinical & Other

    0.91.5-40%Total International28.322.924%Total Sales$

  • During the quarter, Cepheid installed a total of 125 GeneXpert systems in its commercial Clinical business.  Additionally, the Company placed a total of 157 GeneXpert systems as part of its High Burden Developing Country (HBDC) program.  Including the HBDC systems, a cumulative total of 4,117 GeneXpert systems have been placed worldwide as of March 31, 2013.
  • GAAP gross margin on sales was 53% and non-GAAP gross margin on sales was 55%, which compares to 54% and 55%, respectively, in the first quarter of 2012. 
  • Cash and cash equivalents were $102.0 million as of March 31, 2013.
  • DSO was 45 days.
  • Business OutlookFor the fiscal year ending December 31, 2013, the Company continues to expect:

  • Total revenue to be in the range of $375 to $385 million;
  • Net income to range from a net loss of $(0.05) to net income of $0.01 per share; 
  • Non-GAAP net income in the range of $0.41 to $0.46 per share. 
  • Expected non-GAAP net income excludes approximately $29 million related to stock compensation expense and approximately $4 million related to the amortization of acquired intangibles.  The fully diluted share count for the year is expected to be approximately 72 million, except in the event of a GAAP loss where the share count would be approximately 67 million shares.

    The following table reconciles net income (loss) per share to the non-GAAP net income per share range:Guidance Range for YearEnding December 31, 2013Low HighNet Income (Loss) Per Share$
    .01Stock Compensation Expense0.400.39Amortization of Purchased Intangible Assets0.060.06Non-GAAP Measure of Net Income Per Share$
    .46Accessing Cepheid's 2013 First Quarter Results Conference CallThe Company will host a management presentation at 2 p.m. Pacific Time on Thursday, April 18, 2013, to discuss the results.  To access the live webcast, please visit Cepheid's website at at least 15 minutes before the scheduled start time to download any necessary audio or plug-in software.  A replay of the webcast will be available shortly following the call and will remain available for at least 90 days.

    About CepheidBased in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests.  By automating highly complex and time-consuming manual procedures, the Company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases.  Through its strong molecular biology capabilities, the Company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit

    Use of Non-GAAP MeasuresThe Company has supplemented its reported GAAP financial information with non-GAAP measures that do not include employee stock-based compensation expense, amortization of purchased intangible assets and a tax benefit related to an intercompany intellectual property transaction.  The presentation of this additional information is not meant to be considered in isolation or as a substitute for results prepared in accordance with U.S. GAAP.
    The Company's management uses the non-GAAP information internally to evaluate its ongoing business, continuing operational performance and cash requirements, and believes these non-GAAP measures are useful to investors as they provide a basis for evaluating the Company's cash requirements and additional insight into the underlying operating results and the Company's ongoing performance in the ordinary course of its operations.

    These non-GAAP measures may be different from non-GAAP measures used by other companies.  In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles.  The Company believes that non-GAAP measures have limitations in that they do not reflect all of the amounts associated with its results of operations as determined in accordance with U.S. GAAP and that these measures should only be used to evaluate the Company's results of operations in conjunction with the corresponding GAAP measures.

    As described above, the Company excludes the following items from one or more of its non-GAAP measures when applicable:

    Employee Stock-based Compensation Expense. These expenses consist primarily of expenses for employee stock options and employee restricted stock under ASC 718 (formerly SFAS 123(R)).  The Company excludes employee stock-based compensation expenses from its non-GAAP measures primarily because they are non-cash expenses that the Company does not believe are reflective of ongoing operating results in the period incurred.  Further, as the Company applies ASC 718, it believes that it is useful to investors to understand the impact of the application of ASC 718 on its results of operations.

    Amortization of Purchased Intangible Assets.  The Company incurs amortization of purchased intangible assets in connection with acquisitions.  The Company excludes these items because these expenses are not reflective of ongoing operating results in the period incurred.  These amounts arise from the Company's prior acquisitions and have no direct correlation to the operation of the Company's business.

    Tax Benefit Related to Intercompany Intellectual Property (IP) Transaction.  The Company excluded a tax benefit related to an intercompany IP transaction from its results for non-GAAP net loss for the first quarter ended March 31, 2012.  The Company excluded this item as it believes it is non-recurring in nature, and does not have a direct impact on the operation of the Company's core business. 

    Forward-Looking StatementsThis press release contains forward-looking statements that are not purely historical regarding Cepheid's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to potential growth, future revenues and future net income/loss and profitability, including on a non-GAAP basis, and test menu expansion and utilization. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the Company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: our ability to successfully complete and bring on line additional manufacturing lines; our success in increasing direct sales and the effectiveness of our sales personnel; the performance and market acceptance of new products; sufficient customer demand; our ability to develop new products and complete clinical trials successfully in a timely manner for new products; uncertainties related to the FDA regulatory and European regulatory processes; the level of testing at clinical customer sites, including for Healthcare Associated Infections (HAIs); the Company's ability to successfully introduce and sell products in clinical markets other than HAIs; the rate of environmental biothreat testing conducted by the USPS, which will affect the amount of consumable products sold to the USPS; variability in systems placements and reagent pull-through in the Company's HBDC program and the level of sales through that program; other unforeseen supply, development and manufacturing problems; the potential need for additional intellectual property licenses for tests and other products and the terms of such licenses; lengthy sales cycles in certain markets; the Company's reliance on distributors in some regions to market, sell and support its products; the occurrence of unforeseen expenditures, acquisitions or other transactions; costs associated with litigation; the impact of competitive products and pricing; the Company's ability to manage geographically-dispersed operations; and underlying market conditions worldwide.  Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K and its other reports filed with the Securities and Exchange Commission.

    All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.

    FINANCIAL TABLES FOLLOWCEPHEIDCONDENSED CONSOLIDATED UNAUDITED STATEMENTS OF OPERATIONS(in thousands, except per share data)Three Months Ended March 31, 20132012Sales:System and other sales

    5,230Reagent and disposable sales

    75,92862,062Total sales

    91,93877,292Costs and operating expenses:Cost of sales 

    42,89235,608Collaboration profit sharing 

    2,1101,684Research and development

    17,72722,102Sales and marketing

    19,12614,512General and administrative

    9,76311,051Total costs and operating expenses 

    91,61884,957Income (loss) from operations 

    320(7,665)Other income, net

    374238Income (loss) before income taxes

    694(7,427)Benefit from (provision for) income taxes

    (381)1,901Net income (loss)

    (5,526)Basic net income (loss) per share 

    (0.08)Diluted net income (loss) per share 

    (0.08)Shares used in computing basic net income (loss) per share 

    66,82465,02769,40665,027Shares used in computing diluted net income (loss) per share CEPHEIDCONDENSED CONSOLIDATED UNAUDITED BALANCE SHEETS(in thousands)March 31, 2013December 31, 2012ASSETSCurrent assets:Cash and cash equivalents

    95,779Accounts receivable, net


    78,23970,114Prepaid expenses and other current assets 

    12,9079,448Total current assets

    238,180219,340Property and equipment, net

    59,99054,830Other non-current assets

    745913Intangible assets, net


    37,66037,694Total assets

    331,544LIABILITIES AND SHAREHOLDERS' EQUITYCurrent liabilities:Accounts payable 

    33,701Accrued compensation 

    15,92616,540Accrued royalties 

    6,8597,992Accrued and other liabilities 

    3,4724,235Current portion of deferred revenue

    12,3549,599Current portion of notes payable

    186183Total current liabilities 

    82,26372,250Long-term portion of deferred revenue

    1,0091,156Notes payable, less current portion

    1,6411,685Other liabilities

    8,5798,911Total liabilities

    93,49284,002Shareholders' equity:Common stock

    362,012355,867Additional paid-in capital 

    123,806117,217Accumulated other comprehensive income

    75756Accumulated deficit 

    (225,285)(225,598)Total shareholders' equity 

    261,290247,542Total liabilities and shareholders' equity 

    March 31, 20132012Cash flows from operating activities:Net income (loss)

    (5,526)Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:Depreciation and amortization of property and equipment

    3,7682,475Amortization of intangible assets 

    1,5601,441Unrealized exchange differences

    444-Stock-based compensation related to employees and consulting services rendered

    6,2775,498Changes in operating assets and liabilities:Accounts receivable 


    (7,814)(5,457)Prepaid expenses and other current assets 

    (3,528)(3,538)Other non-current assets

    168(768)Accounts payable and other current liabilities 

    8,342(1,600)Accrued compensation 

    (614)(3,071)Deferred revenue 

    2,608251Net cash provided by (used in) operating activities 

    10,477(8,352)Cash flows from investing activities:Capital expenditures 

    (8,929)(4,587)Payments for technology licenses 

    (1,000)-Cost of acquisitions, net

    -(16,992)Net cash used in investing activities 

    (9,929)(21,579)Cash flows from financing activities:Net proceeds from the issuance of common shares and exercise of stock options

    6,14519,409Principal payment of notes payable

    (41)-Net cash provided by financing activities 

    6,10419,409Effect of exchange rate change on cash

    (443)(495)Net increase (decrease) in cash and cash equivalents 

    6,209(11,017)Cash and cash equivalents at beginning of period 

    95,779115,008Cash and cash equivalents at end of period

    3,991CEPHEIDRECONCILIATION OF GAAP TO NON-GAAP MEASURES (UNAUDITED)(in thousands, except per share data)Three Months Ended
    March 31,20132012Cost of sales$
    35,608  Stock compensation expense(542)(635)  Amortization of purchased intangible assets(854)(333)Non-GAAP measure of cost of sales$
    34,640Gross margin on sales per GAAP53%54%Gross margin on sales per Non-GAAP55%55%Operating expenses$
    47,665  Stock compensation expense(5,735)(4,863)  Amortization of purchased intangible assets(374)(316)Non-GAAP measure of operating expenses$
    42,486Income (loss) from operations$
    (7,665)  Stock compensation expense6,2775,498  Amortization of purchased intangible assets1,228649Non-GAAP measure of income from operations$
    (1,518)Net income (loss)$
    (5,526)  Stock compensation expense6,2775,498  Amortization of purchased intangible assets1,228649  Tax benefit related to intercompany IP transaction-(1,815)Non-GAAP measure of net income$
    (1,194)Basic net income (loss) per share$
    (0.08)  Stock compensation expense0.100.08  Amortization of purchased intangible assets0.020.01  Tax benefit related to intercompany IP transaction-(0.03)Non-GAAP measure of net income per share$
    (0.02)Diluted net income (loss) per share$
    (0.08)  Stock compensation expense0.090.08  Amortization of purchased intangible assets0.020.01  Tax benefit related to intercompany IP transaction-(0.03)Non-GAAP measure of net income per share$
    (0.02)Shares used in computing basic net income (loss) per share66,82465,027Shares used in computing diluted net income (loss) per share69,40665,027 

    CONTACTS:For Media Inquiries:For Investor Inquiries:Jared Tipton

    Cepheid Corporate Communications

    Tel: (408) 400 8377

    Jacquie Ross

    Cepheid Investor Relations

    Tel: (408) 400 8329

    SOURCE Cepheid
    Copyright©2012 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Testing Positive for Stability & Growth - Research Report on CombiMatrix Corporation, Cepheid, PerkinElmer, Inc., Life Technologies Corp. and Laboratory Corp. of America Holdings
    2. Cepheid Announces Board of Directors Changes
    3. Cepheid Reports 2012 Second Quarter Results
    4. Cepheid Receives FDA Clearance for GeneXpert Infinity-80 System for Initial Use with Xpert Flu Assay
    5. Cepheid Announces European Release of Xpert CT/NG and Xpert CT, Delivering Rapid Detection and Differentiation of Chlamydia and Gonorrhoeae
    6. Diagnostic Marketing Association Names Cepheid 2011 Marketer of the Year
    7. Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria
    8. Cepheid to Webcast Upcoming Financial Presentations
    9. Cepheid Reports Fourth Quarter and Full Year 2011 Results
    10. Cepheid Welcomes Senior Vice President of Human Resources
    11. Global Nano-Materials Market 2002-2016: Nano-Materials Industry, Production Volumes, Revenues and End User Market Demand - MarketResearchReports.Biz
    Post Your Comments:
    (Date:10/12/2017)... Irvine, ca (PRWEB) , ... October 12, 2017 ... ... for the Surgical Wound Market with the addition of its newest module, US ... the $1.2B market for thrombin hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and ...
    (Date:10/11/2017)... ... October 11, 2017 , ... At ... Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief research scientist ... has been selected for membership in ARCS Alumni Hall of Fame . ...
    (Date:10/11/2017)... CA, USA (PRWEB) , ... October 11, 2017 , ... ... to take place on 7th and 8th June 2018 in San Francisco, CA. The ... influencers as well as several distinguished CEOs, board directors and government officials from around ...
    (Date:10/11/2017)... Netherlands and LAGUNA HILLS, Calif. ... Institute of Cancer Research, London (ICR) ... MMprofilerâ„¢ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with ... known as MUK nine . The University of ... which is partly funded by Myeloma UK, and ICR will ...
    Breaking Biology Technology:
    (Date:7/20/2017)... Delta (NYSE: DAL ) customers now can use fingerprints instead ... National Airport (DCA). ... Delta launches biometrics to board aircraft at Reagan Washington National Airport ... Delta,s biometric boarding pass experience that launched in ... the boarding process to allow eligible Delta SkyMiles Members who are enrolled ...
    (Date:6/14/2017)... -- IBM (NYSE: IBM ) is introducing several innovative partner ... developing collaboration between startups and global businesses, taking place in ... event, nine startups will showcase the solutions they have built ... France is one of ... 30 percent increase in the number of startups created between ...
    (Date:5/16/2017)... 16, 2017   Bridge Patient Portal , ... MD EMR Systems , an electronic medical ... GE, have established a partnership to build an ... the GE Centricityâ„¢ products, including Centricity Practice Solution ... These new integrations will allow healthcare delivery ...
    Breaking Biology News(10 mins):